Collagen type X (with BSA)

X53, Ms

Artikelnummer:CO098-H_RUO
Menge:
Technische Daten
Status:Research Use Only (RUO)
Spezies:Mouse
Ig Unterklasse:IgG1
Immunogen:Human recombinant type X collagen (hrCollX)
Vorbehandlung:ProTaqs® Pronase Digest (Cat. No. 401603497)
Zelluläre Lokalisation:Secreted
Kontrolle:Osteochondroma
Change(s) made:Complete revision
Synonyme:Collagen type X, Col10a 1, Collagen alpha 1(X) chain, Collagen type X alpha 1 (Schmid metaphyseal chondrodysplasia), Collagen type X alpha 1, Collagen X alpha 1 polypeptide, CollagenX, fa66d11, fb10c08, OTTHUMP00000040411, Procollagen type X alpha 1, Schmid metaphyseal chondrodysplasia, wu:fa66d11, wu:fb10c08.
Verfügbar in folgenden Ländern:worldwide
Beschreibung

Type X collagen is a network forming collagen and is synthesized by hypertrophic chondrocytes of the fetal and juvenile growth plate. In various studies type X collagen was identified also in late, degenerative zones of osteoarthritic articular cartilage, in osteophytes and in chondrosarcomas labeling a late, hypertrophic stage of chondrocyte differentiation. This antibody reacts with human native and denatured collagen Type X in hypertrophic cartilage of human fetal growth plate and chondrosarcoma. Treatment of paraffin sections: Proteolytic enzyme digestion of deparaffinized section before staining is necessary. For enhanced results it is recommended to use Pepsin for treatment in following working protocol: = 0,1% Pepsin in 0,5 M acetic acid for 2 hours at +37°C. For Pig coronary vessel, by incubation at 95°C with ProTaqs I Antigen Enhancer Cat# 401602092 solution. After treatment slides must be well soaked with buffer. It is recommended for collagens in hypertrophic cartilage demasking with test. Hyaluronidase. (1-2mg/ml, pH 5,0, 30 min. 37°C.). If the results are nonsatisfying try again with Pepsin at first and afterwards with Hyaluronidase. Treatment of cryostat Sections: Type X Collagen Antibody can be used to label acetone fixed cryostat section or cellsmears too. The optional working dilution should be determined by the individual laboratory.

Literatur

[1] Girkontaite I, et al.: Matrix Biology. 1996;15:231-8.
[2] Sasagawa S, et al.: Development. 2012;139(6):1153-63.
[3] Di Rocco F, et al.: Hum Mol Genet. 2014;23(11):2914-25.
[4] Biosse Duplan M, et al.: Hum Mol Genet. 2016;25(14):2997-3010.
[5] Toh WS, Cao T: Methods Mol Biol. 2015;1307: 263-79.
[6] Nakayama N, et al.: J Cell Sci. 2003;116(Pt 10):2015-28.
[7] Locker M, et al.: J Bone Miner Res. 2004;19(1):100-10.
[8] Brochhausen C, et al.: Arthritis Res Ther. 2006;8(3):R78.

Kontakt